<i>Clostridioides difficile</i>: Treating Sustained Antibiotic Responders With Fecal Microbiota Transplantation Does Not Improve Efficacy

To the Editor—Drekonja et al [1] describe a randomized placebo-controlled trial with lyophilized fecal microbiota transplantation (FMT) capsules to prevent recurrent Clostridioides difficile infection (rCDI). We believe the results should be interpreted cautiously due to trial design aspects, such as the exclusion criteria and primary endpoint.Patients with rCDI face high morbidity and mortality, are notoriously difficult to treat with antibiotics alone, and often require additional therapies such as FMT [2]. Given the high risk of rapid recurrence, current guidelines recommend initiating FMT within 4 days after completing antibiotic treatment for rCDI [3].

Authors

Institutions

Publication Details

Journal
Clinical Infectious Diseases
Published
2025-04-22
DOI
https://doi.org/10.1093/cid/ciaf141
Primary Topic
Clostridium difficile and Clostridium perfringens research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clostridioides difficile: Treating Sustained Antibiotic Responders With Fecal Microbiota Transplantation Does Not Improve Efficacy

Jouzas Kupciskas, Alexander Link, Christian Lodberg Hvas, Tariq Iqbal et al.
2 links
Clinical Infectious Diseases
Clostridium difficile and Clostridium perfringens research
article

Clostridioides difficile: Treating Sustained Antibiotic Responders With Fecal Microbiota Transplantation Does Not Improve Efficacy

Jouzas Kupciskas, Alexander Link, Christian Lodberg Hvas, Tariq Iqbal, Benjamin H. Mullish, Simon Mark Dahl Baunwall, Jens Frederik Dahlerup, Gianluca Ianiro, Josbert J. Keller, Sara Ellegaard Paaske, Maria J G T Vehreshild
article en

Abstract

To the Editor—Drekonja et al [1] describe a randomized placebo-controlled trial with lyophilized fecal microbiota transplantation (FMT) capsules to prevent recurrent Clostridioides difficile infection (rCDI). We believe the results should be interpreted cautiously due to trial design aspects, such as the exclusion criteria and primary endpoint.Patients with rCDI face high morbidity and mortality, are notoriously difficult to treat with antibiotics alone, and often require additional therapies such as FMT [2]. Given the high risk of rapid recurrence, current guidelines recommend initiating FMT within 4 days after completing antibiotic treatment for rCDI [3].

Clinical Infectious DiseasesVol. 81(3)
Università Cattolica del Sacro Cuore (IT), Goethe University Frankfurt (DE), National Health Service (GB), Lithuanian University of Health Sciences (LT), Imperial College Healthcare NHS Trust (GB), Aarhus University (DK), Leiden University Medical Center (NL), Aarhus University Hospital (DK), Agostino Gemelli University Polyclinic (IT), Medisch Centrum Haaglanden (NL), University Hospital Frankfurt (DE), St. Mary’s Hospital (ZA), University Hospital Magdeburg (DE), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Imperial College London (GB), University of Birmingham (GB), Otto-von-Guericke-Universität Magdeburg (DE)
Imperial College London, Imperial College Healthcare NHS Trust, Medical Research Council
Zero hunger
Openalex Percentile: Top 89%
Clostridium difficile and Clostridium perfringens research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.